Jeremiah Velasquez FNP-BC, AGACNP-BC
Summary: MK-4 and MK-7 are both forms of Vitamin K2, but they behave very differently in the body. MK-4 has a serum half-life of 2–4 hours and is rapidly cleared by the liver, making it largely ineffective for reaching bone and arterial tissue at supplemental doses. MK-7 has a half-life of 48–72 hours and achieves sustained extrahepatic tissue saturation at just 180 mcg per day — the dose validated in a 3-year randomized controlled trial.
Walk into any supplement store and grab three different K2 products off the shelf. Odds are, at least two of them contain MK-4.
MK-4 is the more common form — it is less expensive to produce, widely available, and technically correct when the label reads Vitamin K2. So most brands use it.
The problem: at nutritional doses, MK-4 does not produce detectable increases in serum K2 levels. Researchers have confirmed this across multiple studies. In one, 420 mcg of MK-4 daily failed to raise circulating K2 concentrations.
This is not a quality issue. It is a pharmacokinetic one, and understanding the difference is the foundation of making any K2 supplementation actually work.
The Problem: K2 That Does Not Get Where It Needs to Go
Both MK-4 and MK-7 are forms of Vitamin K2. Both can support coagulation factor synthesis in the liver. But the target tissues for bone health and vascular protection are extrahepatic — outside the liver, in peripheral bone and arterial tissue.
Getting K2 to peripheral tissue requires sustained serum presence. The molecule has to stay in circulation long enough to bind to LDL carriers, reach bone and arterial smooth muscle cells, and complete the carboxylation reactions that activate osteocalcin and Matrix GLA Protein.
MK-4 serum half-life: 2–4 hours. It is rapidly taken up by the liver for hepatic coagulation factor production and cleared quickly from systemic circulation. By the time you would need it in peripheral tissue, it is largely gone.
The consequence: to achieve extrahepatic K2 activity with MK-4, researchers have had to use pharmacological megadoses — 45 mg per day or higher. That is not a supplement dose. That is a therapeutic intervention used in clinical trials for specific bone conditions.
At the 100–500 mcg doses most supplements deliver? MK-4 does not make it to bone. It does not make it to the arterial wall. The label is technically accurate. The clinical outcome most people are hoping for is not being achieved.
The Mechanism: Why MK-7 Is Physiologically Different
MK-7 is a longer-chain menaquinone. That structural difference fundamentally changes its pharmacokinetics.
MK-7 serum half-life: 48–72 hours. With a half-life nearly 20 times longer than MK-4, MK-7 achieves something MK-4 cannot: sustained extrahepatic tissue saturation. At 180 mcg/day, MK-7 reaches steady-state concentration in peripheral tissues — including the bone matrix and the smooth muscle cells lining arterial walls.
In bone: MK-7 drives gamma-carboxylation of osteocalcin — osteocalcin gains calcium-binding affinity — mineralization of bone matrix occurs. In arteries: MK-7 activates Matrix GLA Protein — MGP inhibits hydroxyapatite deposition in vascular smooth muscle — arterial calcification is suppressed.
MK-7's tissue distribution and carboxylation activity at 180 mcg have been confirmed in pharmacokinetic studies and validated across long-term human outcome trials. This is not a theoretical model.
For patients managing bone health alongside hormonal health optimization — particularly where testosterone or estrogen influence bone remodeling dynamics — confirming K2 status is a practical clinical consideration. Individuals working with a provider on hormone therapy for long-term bone health may find K2 status an important variable in their broader mineral management protocol. [Steel City HRT & Weight Loss — steelcityhrt.com]
The Solution Angle: What Clinically Validated Actually Means for K2
The MenaQ7® trial is the benchmark. Over 3 years, 244 postmenopausal women received either 180 mcg MK-7 daily or placebo. The MK-7 group showed significantly better preservation of lumbar spine bone mineral density, significantly better preservation of femoral neck bone density, no increase in arterial stiffness (versus meaningful decline in placebo), and regression of arterial stiffness in participants who started with high baseline vascular rigidity.
That last finding is notable. Most interventions can slow arterial aging. Very few demonstrate reversal. The mechanism confirmed: as dp-ucMGP decreased, arterial elasticity improved.
The takeaway for anyone choosing a K2 supplement: the form matters, the dose matters, and the duration of action matters. Choosing MK-4 because it is labeled as K2 is like choosing a delivery vehicle with a 4-hour fuel range for a 24-hour route.
Why BoneShield
BoneShield was formulated around MK-7 specifically because the clinical literature pointed there — and because using MK-4 in a D3/K2 formula designed for bone and cardiovascular outcomes would have been scientifically indefensible.
180 mcg MenaQ7® MK-7 — the patented, standardized form used in the 3-year RCT. Not a proprietary blend. Not an undisclosed amount. The exact dose the research used.
10,000 IU Vitamin D3 — to maximize calcium absorption, induce osteocalcin and MGP production, and create the physiological demand that K2 then meets.
Shop BoneShield K2+D3 at velascosupplements.com
Frequently Asked Questions
Q: What is the difference between MK-4 and MK-7 vitamin K2?
A: MK-4 and MK-7 are both forms of Vitamin K2, but they have dramatically different pharmacokinetics. MK-4 has a serum half-life of 2–4 hours and is largely cleared by the liver at nutritional doses, limiting its ability to reach bone and arterial tissue. MK-7 has a half-life of 48–72 hours, allowing it to achieve sustained tissue saturation at 180 mcg/day.
Q: Does MK-4 work for bone health?
A: At nutritional doses commonly found in supplements, MK-4 does not produce detectable increases in serum K2 levels or consistent evidence of extrahepatic carboxylation activity. Research showing skeletal effects with MK-4 has generally used pharmacological doses of 45 mg per day — far above typical supplement amounts.
Q: What dose of MK-7 is clinically validated for bone and cardiovascular outcomes?
A: The MenaQ7® clinical trial used 180 mcg of MK-7 daily over 3 years and demonstrated preservation of bone mineral density at the lumbar spine and femoral neck, as well as prevention and partial reversal of arterial stiffness. This is the dose BoneShield delivers.
Q: Is 180 mcg of K2 safe to take daily?
A: MK-7 at 180 mcg daily has been studied in clinical trials without significant safety concerns in healthy adults. However, individuals on blood thinners such as warfarin should consult their physician before adding any Vitamin K supplement, as K vitamins interact with anticoagulation therapy.
Q: Why does BoneShield use MenaQ7® specifically?
A: MenaQ7® is the only patented, standardized form of MK-7 with 3-year cardiovascular and skeletal outcome data from a randomized controlled trial. Velasco uses MenaQ7® because it is the form the research actually validated — not a generic MK-7 of uncertain standardization.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before making changes to your supplement regimen or health protocol.